secwatch / observer
8-K filed June 3, 2026, 4:25 PM ET ticker CVKD CIK 0001937993
leadership confidence high sentiment neutral materiality 0.50

Cadrenal Therapeutics CFO Matthew Szot leaves; CEO Quang Pham takes interim CFO role

Cadrenal Therapeutics, Inc.

item 5.02item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Matthew K. Szot

Chief Financial Officer
CVKD · Cadrenal Therapeutics, Inc.
Effective
2026-05-28
Successor
Quang X. Pham
Filed
June 3, 2026, 4:25 PM ET
On May 28, 2026, Cadrenal Therapeutics, Inc. (the "Company") and Matthew K. Szot mutually agreed to his transition from the role of Chief Financial Officer, effective May 28, 2026.
Appointed (interim)

Quang X. Pham

interim Chief Financial Officer and interim Principal Accounting Officer
CVKD · Cadrenal Therapeutics, Inc.
Effective
2026-05-28
Filed
June 3, 2026, 4:25 PM ET
Effective immediately after Mr. Szot's termination, the Company appointed Quang X. Pham, its Chief Executive Officer, as interim Chief Financial Officer and interim Principal Accounting Officer, to serve until a permanent Chief Financial Officer is appointed.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Matthew K. Szot changed role as Chief Financial Officer at Cadrenal Therapeutics, Inc..

Action
mutually agreed to his transition from the role
Role
Chief Financial Officer
Exact text from the filing
On May 28, 2026, Cadrenal Therapeutics, Inc. (the "Company") and Matthew K. Szot mutually agreed to his transition from the role of Chief Financial Officer, effective May 28, 2026.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Quang X. Pham was appointed as interim Chief Financial Officer and interim Principal Accounting Officer at Cadrenal Therapeutics, Inc..

Action
appointed
Role
interim Chief Financial Officer and interim Principal Accounting Officer
Exact text from the filing
Effective immediately after Mr. Szot's termination, the Company appointed Quang X. Pham, its Chief Executive Officer, as interim Chief Financial Officer and interim Principal Accounting Officer, to serve until a permanent Chief Financial Officer is appointed.
View on SEC.gov

Cadrenal Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001213900-26-064744
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.